New drug combo shows promise for Tough-to-Treat biliary cancers
NCT ID NCT02151084
First seen Dec 29, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether adding the targeted drug selumetinib to standard chemotherapy (cisplatin and gemcitabine) helps shrink tumors better than chemo alone in people with advanced bile duct or gallbladder cancer. About 57 adults who have not had prior treatment for their cancer will receive either the drug combo or chemo alone. The goal is to see if the new combination slows cancer growth and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.